Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Pharvaris (NASDAQ:PHVS) Stock Soars 20% Pre-Market on Positive Phase 3 HAE Data

Pharvaris (NASDAQ:PHVS) shares are up 19.66% in pre-market trading to $42.18, after the company announced statistically significant, positive topline results from its pivotal Phase 3 CHAPTER-3 trial evaluating deucrictibant extended-release tablets for prevention of hereditary angioedema attacks. The stock had closed down 1.15% at …

Nitish Kishor | 08 September 2026

Roivant Sciences (NASDAQ:ROIV) Stock Soars 20% Pre-Market on Positive Phase 2 Lung Disease Data

Roivant Sciences (NASDAQ:ROIV) shares are up 19.81% in pre-market trading to $41.85, after its PulmovantSubsidiaryannounced positive Phase 2 PHocus results for mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, a condition with limited treatmentOptionsand high unmet need. The stock had closed …

Nitish Kishor | 08 September 2026

Royalty Pharma (NASDAQ:RPRX) Stock Falls 8% Pre-Market on Novartis Trial Setbacks

Royalty Pharma (NASDAQ:RPRX) shares are down 7.66% in pre-market trading to $59.06, pulling back sharply from Monday's 52-week high near $64.38, in an apparent contagion move tied to Novartis's (NYSE:NVS) late-stage trial failures. Novartis shares fell sharply after both its del-desiran, for myotonic dystrophy, …

Nitish Kishor | 08 September 2026

Why Is This NASDAQ Gene Therapy Stock Down 13% Pre-Market Today?

Shares of this NASDAQ-listed commercial-stage biotechnology company are down 12.76% in pre-market trading to $19.63, falling sharply despite the company's own news today being entirely unrelated to clinical trial data. The decline reflects broad contagion across neuromuscular disease and gene therapy stocks after a …

Nitish Kishor | 08 September 2026

Why Is AstraZeneca (NYSE:AZN) Stock Trading Modestly Higher Pre-Market Today?

AstraZeneca (NYSE:AZN) shares are up 0.31% in pre-market trading to $163.21, as investors weigh a busy stretch of pipeline and regulatory news against mixed analyst signals and broader healthcare sector weakness. The stock closed down 1.26% at $162.70 the prior session, and today's modest …

Nitish Kishor | 08 September 2026

Teleflex (NASDAQ:TFX) Stock: Shares Slip as a New Restructuring Plan Reshapes the Story

Teleflex Incorporated (NASDAQ:TFX) shares slipped at last closing. Teleflex is a maker of single-use medical devices across vascular access, interventional, surgical, urology, and original-equipment and acute-care lines.

Nitish Kishor | 08 September 2026

What Stevanato Group's (NYSE:STVN) Glass Vials Have to Do With Your Medicine Cabinet

● Stevanato Group manufactures glass vials, syringes, cartridges, and drug-delivery devices used to package and administer pharmaceutical products.

Nitish Kishor | 08 September 2026

Why Is Supernus Pharmaceuticals (NASDAQ:SUPN) Under Pressure?

● Supernus Pharmaceuticals is a commercial-stage pharmaceutical company focused on central nervous system disease treatments.

Nitish Kishor | 08 September 2026

Penny Stock Oncolytics Biotech (NASDAQ:ONCY) Slides: Betting on a Binary Cancer Trial Outcome

Oncolytics Biotech Inc. (NASDAQ:ONCY), a penny stock, fell at last closing. Oncolytics is a clinical-stage biotechnology company built around a single lead asset, pelareorep, an intravenously delivered oncolytic virus and immunotherapy being tested in combination with chemotherapy and immunotherapy across several cancers.

Nitish Kishor | 08 September 2026

Why Is Nephros (NASDAQ:NEPH) Losing Ground?

● Nephros designs and sells water filtration products focused on infection control for healthcare facilities and commercial customers.

Nitish Kishor | 08 September 2026
Support

Hi! How can we help you today?

Loading…